Lv4
720 积分 2023-04-17 加入
Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
1天前
待确认
A PD-L1xCD3 bispecific nanobody as a novel T-cell engager in treating PD-L1 overexpression melanoma
1天前
待确认
Novel Bifunctional Conjugates Targeting PD-L1/PARP7 as Dual Immunotherapy for Potential Cancer Treatment
1天前
待确认
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials
21天前
已完结
Programmed death ligand 1 signals in cancer cells
26天前
已完结
Integrating CTLA-4/PD-1 blockade into cervical cancer management: Results of COMPASSION-16
1个月前
已完结
504 CS2009, a novel first-in-class trispecific antibody targeting PD-1, CTLA-4, and VEGFa, demonstrates promising anti-tumor activity in preclinical evaluation
1个月前
已完结
Efficacy of CTLA-4 checkpoint therapy is dependent on IL-21 signaling to mediate cytotoxic reprogramming of PD-1+CD8+ T cells
1个月前
已完结
Bispecific antibodies in oncology
1个月前
已完结
Polyspecificity - An emerging trend in the development of clinical antibodies
1个月前
已完结
皖公网安备34019202002308
